Search
43 studies match these filters. Showing 1–25 of 43 studies
| Registration number | Study | Status | Phase | Enrolment | Sites / countries | Start year | Last updated | Actions |
|---|---|---|---|---|---|---|---|---|
| NCT07619131 | A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients. This is a study to evaluate the effect on LDL-C and the safety and tolerability of FDC laroprovstat/rosuvastatin in LLT-naïve patients. Laroprovstat is a small molecule that reduces the amount of LDL-C in the blood. Laroprovstat and FDC laroprovstat/rosuvastatin are being developed for the treatment… ✓ Contact✗ Claimed Nearest site: Derby, Kansas, United States — 54 km away · 152 sites in total | Recruiting | Phase 3 | 600target | 152 / 11 | 2026 | Sep 10, 2026 | |
| NCT07667803 | A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exerci… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 325 sites in total | Recruiting | Phase 3 | 4,500target | 325 / 19 | 2026 | Sep 9, 2026 | |
| NCT07684144 | Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 37 sites in total | Recruiting | Phase 3 | 950target | 37 / 3 | 2026 | Sep 3, 2026 | |
| NCT07284901 | Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c) ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 167 sites in total | Recruiting | Phase 3 | 1,156target | 167 / 11 | 2026 | Sep 3, 2026 | |
| NCT07684235 | Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839). ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 87 sites in total | Recruiting | Phase 3 | 3,200target | 87 / 4 | 2026 | Sep 3, 2026 | |
| NCT07284979 | Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight. ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 59 sites in total | Recruiting | Phase 3 | 1,200target | 59 / 5 | 2025 | Sep 1, 2026 | |
| NCT07564414 | A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive eith… ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 303 sites in total | Recruiting | Phase 3 | 2,500target | 303 / 19 | 2026 | Aug 31, 2026 | |
| NCT07662044 | A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron alone or in combination with dapagliflozin compared with placebo in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucos… ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 149 sites in total | Recruiting | Phase 3 | 800target | 149 / 13 | 2026 | Aug 31, 2026 | |
| NCT07654374 | A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2) This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatment. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 74 sites in total · contact listed | Recruiting | Phase 3 | 1,100target | 74 / 1 | 2026 | Sep 11, 2026 | |
| NCT07606066 | A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient population across different geographical regions. ✓ Contact✗ Claimed Nearest site: El Dorado, Kansas, United States — 85 km away · 76 sites in total | Recruiting | 2,150target | 76 / 7 | 2026 | Aug 25, 2026 | ||
| NCT07282743 | Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus This is a phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of GL0034 among type II diabetes mellitus subjects who are obese or overweight with weight-related comorbidities. Subjects will be put on either one of the four treatment arms (GL0034, on… ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 21 sites in total | Recruiting | Phase 2 | 285target | 21 / 2 | 2026 | Mar 18, 2026 | |
| NCT07546929 | HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes Blood sugar levels are controlled by insulin, a hormone made by cells in the pancreas. After a meal, carbohydrates are broken down into glucose which is absorbed from the intestine into the blood leading to a rise in glucose (blood sugar) which triggers the secretion of insulin. Insulin binds to cel… ✓ Contact✗ Claimed Nearest site: El Dorado, Kansas, United States — 85 km away · 25 sites in total · contact listed | Recruiting | Phase 2 | 300target | 25 / 1 | 2023 | Apr 23, 2026 | |
| NCT07296484 | Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 61 sites in total · contact listed | Recruiting | Phase 2 | 1,500target | 61 / 1 | 2025 | Sep 9, 2026 | |
| NCT07654361 | Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1) Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calor… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 71 sites in total · contact listed | Recruiting | Phase 3 | 3,600target | 71 / 1 | 2026 | Aug 10, 2026 | |
| NCT07662213 | A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 209 sites in total | Recruiting | Phase 3 | 1,200target | 209 / 15 | 2026 | Sep 9, 2026 | |
| NCT07353931 | Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last abo… ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 152 sites in total · contact listed | Recruiting | Phase 3 | 900target | 152 / 14 | 2026 | Sep 8, 2026 | |
| NCT06628908 | Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 76 sites in total | Recruiting | Phase 3 | 1,100target | 76 / 1 | 2024 | Jun 15, 2026 | |
| NCT06190717 | Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial This is a prospective, multi-center, two-arm, randomized trial to quantify the performance of the EchoMark®/EchoSure® System for AVF diagnostic ultrasound when used under a protocol of biweekly use for assessing fistula maturation and reducing time to Clinical Maturation. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 21 sites in total · contact listed | Recruiting | Not applicable | 304target | 21 / 1 | 2024 | Apr 13, 2026 | |
| NCT07165028 | A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasi… ✓ Contact✗ Claimed Nearest site: El Dorado, Kansas, United States — 85 km away · 563 sites in total · contact listed | Recruiting | Phase 3 | 4,500target | 563 / 34 | 2025 | Sep 8, 2026 | |
| NCT07153471 | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks. ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 88 sites in total · contact listed | Recruiting | Phase 3 | 800target | 88 / 7 | 2025 | Sep 8, 2026 | |
| NCT07567001 | A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to fi… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 838 sites in total | Recruiting | Phase 3 | 5,610target | 838 / 27 | 2026 | Aug 18, 2026 | |
| NCT07610278 | A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia This is a multicenter, randomized, double-blind, factorial design Phase 2 study to evaluate the pharmacodynamics, safety and tolerability of a combination of QCZ484 and inclisiran compared to QCZ484, inclisiran, and placebo in participants with hypertension and concomitant hypercholesterolemia. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 29 sites in total · contact listed | Recruiting | Phase 2 | 120target | 29 / 1 | 2026 | Jul 30, 2026 | |
| NCT07037459 | Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fract… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 657 sites in total | Recruiting | Phase 3 | 5,056target | 657 / 34 | 2025 | Sep 16, 2026 | |
| NCT06215716 | A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 356 sites in total | Recruiting | Phase 3 | 1,650target | 356 / 18 | 2023 | Aug 7, 2026 | |
| NCT04852887 | De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 832 sites in total · contact listed | Recruiting | Phase 3 | 1,670target | 832 / 4 | 2021 | Apr 23, 2026 |